


Cabbacis Inc. (CABI)

Company Overview

Cabbacis is a U.S.-licensed tobacco-product developer working on cigarettes and vaporizer pods made from reduced-nicotine tobacco blended with hemp. The company wants to give smokers a less harmful option that still feels familiar. Its long-term plan is to sell its own iBlend™ products while also licensing its technology to partners around the world.



Key Highlights

- Holds more than 35 issued patents covering reduced-nicotine tobacco and hemp blends.
- iBlend™ products use about 95% less nicotine than major U.S. cigarette brands.
- First U.S. PMTA filing planned for January 2026, targeting near-term commercialization.
- Completed a pilot clinical trial showing strong satisfaction and reduced cravings.
- Global licensing strategy creates multiple ways to scale without high costs.
- Qualified for a Regulation A offering to raise up to \$7M for commercial efforts.
- Positioned to benefit from expected nicotine-cap rules and global harm-reduction trends.

Market Opportunity

The global tobacco market is worth hundreds of billions of dollars, with more than one billion smokers worldwide. Many countries are moving toward lower-nicotine rules and harm-reduction alternatives. Cabbacis aims to fit directly into this shift by offering reduced-nicotine + hemp products. The addressable market includes the U.S., China, Europe, Brazil, and Japan, where most smokers live. If nicotine-reduction laws advance, demand for products like iBlend™ could rise quickly, creating a large licensing and product-sales opportunity.

Competitive Positioning

Cabbacis has a strong patent portfolio that covers both cigarettes and vaporizer pods across major global markets. Its dual strategy—building its own brand while licensing to bigger partners—helps the company grow without needing massive capital. The technology is aligned with future nicotine-cap rules, giving the company a first-mover advantage. These factors create a niche moat in a heavily regulated, high-barrier industry.

Financial Snapshot & Traction

Revenue	No commercial revenue as of 2024–2025 (development stage).
Net loss for six months ended June 30, 2025	\$735,560 (vs. ~\$299,480 in 2024).
Patent progress	U.S. Patent No. 12,349,724 issued for tobacco-hemp vaporizer pods.
Clinical milestone	Pilot trial showed strong user satisfaction and reduced cravings.
Regulation A raise	Seeking up to \$7M to fund PMTA, partnerships, and commercialization.
Cash (mid-2024)	\$1.03M, with very low debt and total assets of ~\$1.9M.